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CWe conducted a two-stage study in France, Germany, Italy, Spain, Swe-
den, and the United Kingdom of the stated preferences of chronic pain
sufferers treated with classic strong opioids and of physicians treating
such patients. The qualitative stage identified attributes perceived im-
portant through focus groups with 84 pain sufferers and semistruc-
tured interviews with 11 physicians. The quantitative stage included
online, discrete choice experiments (DCEs) inwhich respondents chose
between hypothetical profiles or an opt-out in 15 choice tasks. The
profile descriptions were based on the attributes elicited in the quali-
tative stage. DCEs were conducted for pain sufferers (N  242) and
physicians (N 270) who passed a rationality test. Main-effectsmodels
were estimated by hierarchical Bayesian regression. Sufferers ranked
nausea, pain impact, energy, alertness, and constipation; physicians
ranked pain response, central nervous system (CNS) effects, nausea, O
ealth
al So
doi:10.1016/j.jval.2011.07.002ose form, and constipation in descending order of importance. Suffer-
rs were unwilling to incur severe side effects to decrease pain and
hose the opt-out in approximately one half of the choice tasks,
hereas physicians were willing to trade between profiles. Themodels
redicted physicians’ choices better than those of pain sufferers. No
ge, sex, or country effects were seen, but stronger preferences were
ound among physicians treating noncancer (n  40) than cancer pain
nd among the 55% of sufferers who had never discontinued long-term
ainmedication use. Sufferers’ mean pain scores on an 11-point Likert
cale were 4.0, 5.7, and 8.6 on their best, average, and worst days, re-
pectively.
eywords: chronic pain, opioids, stated preference.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic pain imposes a substantial burden due to its preva-
lence, severity, and impact on quality of life and work partici-
pation. A large survey in 15 European countries and Israel [1]
found that almost one in five adults experienced chronic pain of
moderate to severe intensity, which seriously affected their
quality of life.
According to the World Health Organization (WHO) three-step
“pain ladder,” classic strong opioids, which include the pure -re-
ceptor agonist morphine and synthetic analogues, are used as
third-step treatment options. Their role in cancer pain [2–4] and in
chronic noncancer pain [5] is supported by clinical guidelines and
recommendations. Due to concerns about side effects and the
risks of physical tolerance or addiction, strong opioids are mostly
used in the oncology setting.
A systematic review of 18 randomized trials of WHO step 3 opi-
oids [6] found mean pain relief of about 30%. Dose was frequently
limitedby side effects, themost commonofwhichwere constipation
(41%), nausea (32%), and somnolence (29%). Sufferers desire pain re-
* Address correspondence to: Jeremy Chancellor, Chancellor H
PL30 3ET, UK.
E-mail: jeremy@chancellorhealtheconomics.com.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.lief, but if they cannot tolerate medication, they may prefer to live
with a degree of pain, whereas physicians are obliged to balance
subjective assessment of pain, side effects, and patient factors.
Hence, chronic pain sufferers and physicians face trade-offs alike.
In this study, we sought to gain amore detailed understanding
of these trade-offs. Such insights should help providers of pain
services respond to patient preferences. Second, by understanding
physician preferences, manufacturers canmore closely align drug
development with clinical need. Third, researching similarities
and differences between perceptions of sufferers and those of
physicians may foster a mutual understanding with respect to
treatment choices and realistic expectations of outcomes.
Our first objective was to identify the attributes of greatest in-
terest to physicians and pain sufferers when they consider pre-
scribing or taking strong opioids for chronic pain. The second aim
was to evaluate the relative strength of preference for these attri-
butes and how respondents trade between them. The third objec-
tive was to identify similarities and differences between the atti-
tudes of physicians and pain sufferers in six countries: France,
Germany, Italy, Spain, Sweden, and the United Kingdom.
Economics Ltd., The Barn House, St. Kew, Bodmin, Cornwall,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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107V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 6 – 1 1 7Among methods for eliciting stated preferences, discrete choice
experiments (DCEs) were originally developed for use in marketing
research [7]. In the past decade or so, the value of DCEs for research-
ing health-care preferences has been recognized [8,9], with pain re-
search [10–14] beingoneofmanyapplications. In aDCE, respondents
re typically asked to choose betweenhypothetical profiles of a good,
hich differ only in the levels at which selected attributes are pre-
ented. Making such choices forces respondents to trade between
ttributes in choosing their preferred profile.
Methods
Qualitative phase
Before designing the DCEs, we conducted qualitative research to
identify the opioid treatment attributes that sufferers and physi-
cians considered most important. Between December 2008 and
March 2009, focus group discussions were conducted among a to-
tal of 44 sufferers of osteoarthritis or low back pain (hereafter re-
ferred to as noncancer pain) and 40 sufferers of cancer pain, with
one group in each indication in each of the six countries. Each
group was moderated by a professional local market researcher
and targeted six to eight adult respondents who had suffered pain
and had been taking classic strong opioids for at least 6 months.
Concurrently, semistructured interviews were conducted among
physicians with substantial practices in treating chronic noncancer
pain due to either osteoarthritis or low back pain or cancer pain and
whohad experience in the use of classic strong opioids. These differ-
ing interviewmethods for sufferers and physicians were chosen for
reasons of practicality [15]. The prevalence of chronic pain allowed
enough sufferers to be recruited for focus groups, the interactive na-
ture of which was considered desirable. As it would not have been
possible to recruit sufficient numbers of opioid prescribers for focus
groups, semistructured telephone interviews were preferred for the
physicians. We recruited 9 physicians against a target of 12 (i.e., one
physician per indication in each country). All six countries were rep-
resented, with four respondents who treated noncancer pain and
five who treated cancer pain. The pain sufferer and physician re-
spondents were recruited through lists maintained by commercial
market research agencies. All focus groups and interviewswere dig-
itally recorded, and themoderators and interviewers prepared sum-
mary transcripts using a pre-prepared document template based on
the discussion and interview guides. Three of the authors (J.C., M.M.,
andH.L.) attendedoneormore focus groups behindone-way glass to
hear proceedings in person and to verify the quality of the work.
From the transcripts, tabular summaries of the qualitative content
were developed in which, for example, counts were made of key-
words mentioned related to medication and side-effect concerns.
Attribute and level definition
Attributes and levels for the choice taskswere developed using the
tabular summaries of the qualitative findings (see Results section).
The response patterns suggested that separate DCEs would be re-
quired for the physicians and the pain sufferers, whereas cancer
pain and noncancer pain could be handled by quota sampling in
each DCE. For each group, five attributes were identified as most
important; each of which was described at three levels. The attri-
bute and level descriptions are shown in Table 1 in the expected
rder of preference, i.e., level 1 was expected to be rated best, level
intermediate, and level 3 worst, although profiles were devoid of
ny such labeling when presented to respondents.
Sampling frame
The DCE was designed as a Web-based questionnaire. The sam-
pling frame consisted of members of Internet panels maintained
by Research Now (10,000 chronic pain sufferers) and WorldOneResearch (23,000 specialist physicians). These providers operate
a strict policy of recruiting panels, and selecting samples for indi-
vidual studies, by invitation only. It was intended to obtain sam-
ples of 300 sufferers and 300 physicians, 50 per country. Quotas
were set for an even split between cancer and noncancer chronic
pain, the latter limited to osteoarthritis, low back, or other mus-
culoskeletal pain. Sufferers had to have been suffering from sig-
nificant pain for at least 6 months and taking opioid medication.
Physicians had to be treating at least 10 chronic pain sufferers per
month who required classic strong opioids. Respondents were
screened online against these inclusion criteria.
Experimental design
The DCEs consisted of 15 choice tasks. In each task, respondents
were asked to make a “discrete choice” between 2 profiles, in
which attribute levels were varied. They could opt out if they pre-
ferred neither profile. Respondents opting out of all 15 choice tasks
were designated as “nontraders” over the range of the levels pre-
sented and were eliminated from main analysis [9]. Only 12 tasks
were used in themain analyses, the other 3 being “holdout” tasks.
The first task was a “rationality” holdout in which the one profile
was considered to dominate the other; respondents who failed
this test were eliminated from the main analysis. This holdout
always appeared as the first task and served as a warm-up exer-
cise. Two holdouts dispersed within the overall exercise tested
consistency by repeating an identical choice. Inconsistent re-
sponders were retained in the main analysis sample.
Although theholdout taskswere specified by the researchers, the
experimental design for the 12main analysis taskswas generated in
a specialized software package, Sawtooth SSIWeb, version 6.4 (Saw-
tooth Software Inc., Sequim, WA), as a choice-based conjoint analy-
sis. A “balanced overlap” algorithm was chosen that produced a de-
sign for each respondent that is as close to orthogonal as possible for
main effects while minimizing repetition of levels in any one task.
Therewere no prohibited combinations of attribute levels. One hun-
dred questionnaire versions were developed. The order of appear-
ance of attributes was fixed, and no attempt was made to sort the
order of the two profiles, although a “none of these” opt-out choice
always appeared to the right of the two profiles.
Questionnaire design
Potentially eligible sufferers and physicians completed local lan-
guage versions of their respective Web-based questionnaires. If
confirmed eligible in screening, respondents were granted access
to the main questionnaire, where they completed the DCE and
provided demographic, history, and treatment experience data.
Sufferers were asked to rate their pain on an 11-point Likert scale.
The DCE and overall questionnaire were designed to be easy to
self-complete, with carefully designed text and graphic elements in
the screens and response-contingent routing. The questionnaires
were carefully worded with language appropriate to the respondent
group. Progress bars and reassurance or error messages were incor-
porated to encourage completion. Drafts of the questionnaires were
piloted online among the researchers’ colleagues and then “soft
launched” to respondents before being finalized. Figure 1 shows a
sample choice task as presented to pain sufferers; this is the ratio-
nality holdout task. Appendixes 1 and 2 (found at doi:10.1016/
j.val.2011.07.002) show the entire questionnaires.
Model estimation
Initial analysis of responses was performed as counts for respon-
dents in total and by response to the rationality test question. For
main effects of each attribute and all two-way interactions be-
tween attributes, the proportion of times that each level or com-
bination of levels was chosenwas determined, alongwith the pro-
portion of times the “none of these” option (i.e., the opt-out) was
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108 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 6 – 1 1 7chosen. Chi-square tests were performed for differences between
observed and expected proportions under null hypotheses that
respondents were indifferent between attribute levels.
Main effects and first-order interactions for potential inclusion in
the model were determined by fitting a multinomial logit (MNL)
model by iterativemaximum likelihood estimation. Candidatemod-
els were compared to a null model by obtaining chi-square statistics
for the difference between the 2-log likelihood statistics for each it-
eration and the null model. Difference in fit after inclusion of inter-
action terms were tested in similar fashion. Root likelihood (RLH)
valueswere obtained as the geometricmean of the probabilities cor-
responding to the choices made by respondents. RLH values were
compared to the best possible value (1) andworst possible value (the
reciprocal of the number of choices per task, i.e., 1/3 0.33).
MNL models were estimated on the first two levels of each
attribute, omitting the third to avoid dependencies. The third-
level effect was represented by effects coding, such that the coef-
ficients for three levels summed to zero. Estimation was con-
ducted in Sawtooth SMRT version 4.18 (Sawtooth Software Inc.).
Table 1 – Attribute and level descriptions.
Attribute
A. Descriptions for pain sufferers
Effect of medication on your pain
Constipation and bowel problems
Nausea and vomiting
Alertness
Energy
B. Descriptions for physicians
Range of dosage forms
Proportion of patients achieving at least 50% pain reduction
Side effects
Constipation
Nausea and vomiting
Central nervous system
C. Severity definitions for side-effect descriptions to physicians in B
None or mild
Constipation Physician advice and prophylaxis
only
Nausea and vomiting Transient, resolves within a few
days of starting treatment
CNS No complaints from patient
Each profile presented to respondents consisted of five statements, cThe best-fit MNLmodel was selected for re-estimation using hier-
parchical Bayesian analysis, which was performed using Sawtooth
CBC/HB version 4.6.4 (Sawtooth Software Inc.).
The hierarchical Bayesian model has two levels. At the upper
level, respondents are considered to be members of a population
of similar individuals, whose part-worths are assumed to be dis-
tributed multivariate normal:
iN,D,
where i is a vector of part-worths for the ith individual,  is a
ector ofmeans of the distribution of individuals’ part-worths and
is a matrix of variances and covariances of the distribution of
art-worths across individuals.
At the lower level, the probability that an individualwill choose
particular alternative from a set of alternatives is assumed to be
escribed by an MNL model. Formally, the probability of the ith
ndividual choosing the kth alternative in a particular task is:
exk′i
els
n not preventing any usual activities
n preventing some usual activities
n preventing basic activities: cannot go out
ne or very slight
ling bloated, sluggish, uncomfortable
evacuation for several days, abdominal pain
ne or very mild and occasional
useous: cannot do usual activities
sistent vomiting and retching
concentrate well
getful, hard to concentrate
ling out of control, difficulty talking
t sleepy
ling sleepy, lazy or apathetic
not stay awake, just want to sleep
de range: oral, parenteral. and transdermal
ited range: oral and parenteral
enteral only
of patients
of patients
of patients
ne or mild (75%), moderate (25%)
ne or mild (25%), moderate (70%), severe (5%)
derate (25%), severe (75%)
ne or mild (75%), moderate (25%)
ne or mild (25%), moderate (70%), severe (5%)
derate (25%), severe (75%)
ne or mild (75%), moderate (25%)
ne or mild (25%), moderate (70%), severe (5%)
derate (25%), severe (75%)
Moderate Severe
ptoms managed with daily
axatives
Symptoms distressing enough
to discontinue opioid
ptoms managed by
reatment with anti-emetics
Symptoms distressing enough
to discontinue opioid
ptoms managed by
djustment of opioid dose
Symptoms distressing enough
to discontinue opioid
ising one level of each attribute.Lev
Pai
Pai
Pai
No
Fee
No
No
Na
Per
Can
For
Fee
No
Fee
Can
Wi
Lim
Par
75%
50%
25%
No
No
Mo
No
No
Mo
No
No
Mo
Sym
l
Sym
t
Sym
ak
je
xj′i
l109V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 6 – 1 1 7where xj is a vector of values describing the jth alternative in that
choice task.
The indirect utility function to be estimated for an individual i
for a hypothetical product profile takes the following form:
Ui0l1X1l2X2 ...lnXn eu
where X1 . . . Xn are product attributes that may occur at specified
levels l,  is a constant, and    are coefficients specific to the
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tails of the iterative estimation algorithm are available at the soft-
ware publisher’s Web site [16].
Diagnostics were performed on the estimated model using re-
sponses to the holdout tasks, which were not used for model esti-
mation. Rationality was reported as the proportion of respondents
who provided the expected “rational” response to holdout task 1.
Consistency was reported as the proportion of respondents who
chose the same profiles or opted out in both of the identical hold-
out questions 2 and 3. Using only the consistent responders, the
estimatedmodel was used to predict the choices actually made in
holdouts 2 and 3. Given a perfect model, respondents would be
expected to choose the profile with the greater estimated individ-
ual utility, i.e., the sum of the estimated part-worths over the five
attribute levels and the constant, or the opt-out if it had greater
utility than either profile. For each respondent, the predicted
choice and actual choice were compared. Predictive ability was
reported as the proportions of correct predictions for each of the
three possible choices (profile 1, profile 2, and opt-out).
Analyses of respondent preferences
Themain analyses for each substudy were the calculation of part-
worths, which were reported as the means of individuals’ part-
worths estimated by the hierarchical Bayesian process. Ordering
of levels was compared to expectations by examination of the
signs and magnitude of the part-worth coefficients. The strength
of preference for each attribute was calculated as the absolute
difference between the highest and lowest scoring level under the
effects coding scheme. The relative importance of each attribute
over the ranges studied was calculated by dividing the sum of
difference in part-worths between the highest and lowest level
into the sum of this statistic over all attributes. Potential associa-
tions between sufferer and physician characteristics and strength
of preferences were explored using t tests or one-way analysis of
variance, as appropriate.
Results
Qualitative findings
Chronic pain sufferers
For chronic pain sufferers, one cancer pain focus group and one
noncancer pain focus group were conducted in each of the 6
countries, achieving a total of 40 and 44 participants, respec-
tively. Sufferers described their pain and the effects of medica-
tion in terms of the impact on their daily activities. They re-
garded complete freedom from pain as an unrealistic objective,
with several respondents stating that they were prepared to
settle for pain mild enough to allow usual activities of daily
living without intolerable side effects. They hoped that new
treatments might reduce pill count but did not expect their pain
to be entirely eradicated. Only a few respondents claimed that
doctors did not understand their condition. Among the side ef-
fects of opioids seen as most bothersome, pain sufferers re-
garded chronic constipation as not only distressing but unpre-
dictable. If it became more severe, such that days went by
without evacuation despite laxatives, the risk of urgency forced
sufferers to plan their activities so they were never far from a
toilet. Respondents stated that nausea could range from mild
and short-lived to more severe and persistent, forcing them to
lie down and do nothing, and particularly debilitating if it
caused retching and vomiting. Central nervous system (CNS)
effects experienced by respondents ranged from drowsiness,
apathy, and lack of concentration to more distressing symp-toms such as hallucinations or “out-of-body” feelings. Some re-
spondents commented that speech could be affected, such that
they knew what they wanted to say but could not get the words
out. Among CNS effects, loss of alertness and lack of energy
appeared to be distinct from each other, the former relating to
mental acuity and the latter to sleepiness and general apathy.
Dependency was recognized as a risk of classic opioids but
could be minimized, along with side effects and tolerance, by
using these medications sparingly. Users would titrate the dose
to achieve a satisfactory balance between pain control and lack
of side effects.
Physicians
A total of 11 respondents were recruited for the semistructured
interviews: 6 physicians who treated mainly noncancer pain
and 5 who treated cancer pain. Physicians stated that they tend
to tailor analgesia to type and severity of chronic pain. Classic
strong opioids were used in most patients with cancer pain, but
in noncancer pain they were reserved for pain not controlled by
other means. Physicians remarked that the etiology of low back
pain is multifactorial, often with a neuropathic component,
which might prompt a trial of tricyclic antidepressants or anti-
convulsants. Opioids were perceived as effective and necessary
in chronic nociceptive pain. A common theme was that physi-
cians expected opioids to be available in a wide range of dose
forms to allow treatment to be tailored to individual patients
and rotated if necessary. Physicians try to minimize dosage fre-
quency for ambulatory patients by using extended-release oral
or transdermal formulations.
Physicians were well aware of the trade-offs between effi-
cacy and side effects and took an empirical approach to moni-
toring patients and managing side effects. Dose adjustment
would be the first response, involving titration to a level that
reduced side effects to a manageable level while maintaining
adequate pain control. If this approach failed, then the patient
would be switched to another treatment. When initiating treat-
ment, physicians counseled patients to expect gastrointestinal
and CNS side effects to some extent and act accordingly, such as
increasing fluid and roughage intake to minimize constipation.
If constipation became a problem, laxatives would be the next
line of management. Physicians warned patients to expect nau-
sea on starting treatment, but that it would probably subside
after 2 or 3 weeks. If persistent, it could be managed with anti-
emetics. Patients were instructed to expect some drowsiness
and to adjust their activities if necessary. More severe CNS prob-
lems, such as speech difficulties and hallucinations, would dic-
tate discontinuation. Dependence and tolerance were thought
to be manageable and not a barrier to use. The risk of depen-
dence was regarded as less of a concern for cancer patients than
for others. Physicians would limit the supply of opioids to pa-
tients with noncancer pain if they were deemed at risk of abuse.
Physicians tended to assess pain quantitatively. Most com-
monly mentioned was an 11-point rating scale from 0 (“no
pain”) to 10 (“worst pain imaginable”). Also mentioned were
responder rates, such as the proportion of patients achieving a
minimum 50% pain reduction, and pain intensity question-
naires.
Quantitative findings
Chronic pain sufferers
Of a total of 10,021 members of the pain panel who responded to
invitations to participate, 303 were initially admitted to the study
after screening. Themain reason for disqualificationwas failure to
meet the pain history andmedication entry criteria. A further rea-
son was that the necessary quotas of cancer pain and noncancer
111V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 6 – 1 1 7pain in each country resulted in some respondents being elimi-
nated as “over quota.” On initial examination of the data, 127 re-
Table 2 – Respondent characteristics: pain sufferers.
Respondent characteristic
Country and pain type U
U
Fr
Fr
G
G
It
It
Sp
Sp
Sw
Sw
Age 
30
40
50

Sex M
Fe
Diagnoses (multiple diagnoses possible) O
C
O
R
In
A
A
C
Time on opioid medication Le
1–
3

Ever experienced side effects from opioid medication Y
N
Ever discontinued chronic pain medication Y
N
Reasons, among those discontinuing (n  133);
multiple reasons allowed
N
M
M
O
Satisfaction with available strong opioids V
Fa
N
Fa
V
Age stopped continuous, full-time education, in years 
16
19
22

Ethnic background W
O
D
Totalspondents had completed the questionnaire in less than 10 min-utes and were largely responsible for an unexpectedly high
number of incorrect responses in the rationality test. These “hur-
Category N Proportion,
%
cer pain 19 8
ncancer pain 26 11
, cancer pain 16 7
, noncancer pain 29 12
ny, cancer pain 20 8
ny, noncancer pain 24 10
ancer pain 20 8
oncancer pain 19 8
cancer pain 15 6
noncancer pain 24 10
n, cancer pain 14 6
n, noncancer pain 16 7
ars 31 13
ears 48 20
ears 76 31
ears 57 24
ars 30 12
101 42
141 58
rthritis 68 28
c lower back pain 157 65
usculoskeletal pain 127 52
atoid arthritis 50 21
matory arthritis 52 21
sing spondylitis 24 10
ain 110 45
104 43
an 1 month (just started) 15 6
38 16
year 69 29
r 120 50
181 75
61 25
133 55
109 45
ger needed medication 13 10
tion not effective 20 15
tion caused side effects 90 68
eason 27 20
tisfied 22 9
atisfied 111 46
l 68 28
issatisfied 34 14
issatisfied 7 3
25 10
87 36
53 22
47 19
30 12
226 93
14 6
d to respond 2 1
242 100K, can
K, no
ance
ance
erma
erma
aly, c
aly, n
ain,
ain,
ede
ede
30 ye
–39 y
–49 y
–59 y
60 ye
ale
male
steoa
hroni
ther m
heum
flam
nkylo
cute p
ancer
ss th
3 mo
mo–1
1 yea
es
o
es
o
o lon
edica
edica
ther r
ery sa
irly s
eutra
irly d
ery d
16
–18
–21
–25
25
hite
ther
eclineriers” were eliminated as invalid and were replaced with fresh
B112 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 6 – 1 1 7respondents until the study sample of 306 was reached. Replace-
ment of hurriers, some necessary relaxation of strict quotas, and
post-fieldwork disqualification of 46 irrational and 18 nontrading
responders resulted in an analysis sample of 242 “rational trad-
ers.” The composition by country and pain type and characteris-
tics of the final analysis sample is shown in Table 2.
Fig. 2 – Estimated mean part-worths for sufferers (N = 242). T
for each attribute and level, and a constant term, for each in
(CIs) of these statistics; the means represent the regression
magnitudes represent the relative importance of each attrib
in utility between levels for the purposes of illustrating likel
ayesian measure of the model fit.The count data showed significant preferences among levelsfor all five attributes for the main analysis sample, consistent
with expectations, but not for those who failed the rationality
test. Even in the main sample, the opt-out was preferred in as
many as 52% of all choice tasks, suggesting that respondents
found most of the presented profiles unacceptable. Some rever-
sals of preferences were observed. Although the expected or-
ierarchical Bayesian model estimates mean part-worths
ual. The table shows means and 95% confidence intervals
cients in the estimated main-effects model. The mean
The chart expresses the mean part-worths as differences
ding behavior. The pseudo R2 value is a hierarchicalhe h
divid
coeffi
ute.
y tradering of levels 1  2  3 was observed for the dimensions of
ad
3
r
g
w
w
t
113V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 6 – 1 1 7constipation, nausea, and energy, levels 2 and 3 were reversed
for pain and alertness.
Results of the model diagnostics are shown in Appendix 3
found at doi:10.1016/j.val.2011.07.002. In the consistency test, 186
(77%) of respondents chose consistently. These 186 formed the
sample for the test of predictive ability. The model correctly pre-
dicted 103 of the 119 choices of profile 2, but it incorrectly pre-
dicted that profile 2 would be chosen by 61 respondents who ac-
tually chose profile 1 or the opt-out.
A main-effects model based on five attributes was estimated
and the mean part-worths are shown in Figure 2. Sufferers
ranked attributes in the following descending order of impor-
tance: nausea, pain, energy, alertness, and constipation, al-
though the narrow range between attributes in overall strength
of preference suggests that pain sufferers take all attributes into
account in forming preferences. Given the observed preference
reversals and relatively weak predictive ability of the model,
any inferences about sufferers’ trading behavior require cau-
tion. The plot of differences between part-worths of levels sug-
gests possible trading behavior between alternative scenarios.
Marked differences in preference are apparent between the
most preferred level (level 1) of each of the four side-effect at-
tributes and the intermediate level, which is level 2 for consti-
pation, nausea, and energy and level 3 for alertness. This effect
is greatest for nausea. Hence, it can tentatively be inferred that
to avoid feeling “nauseous: cannot do usual activities,” sufferers
would accept some problems with any one of the other three
types of side effect. Taking the preference reversal between lev-
els 2 and 3 of pain at face value, the results suggest that given
“pain preventing basic activities” (level 3) and side effects all at
level 1, respondents would rather accept this level of pain rather
than incur any one side effect at worse than level 1. The main-
effects model assumes an additive relationship between attri-
butes, which suggests that the difference between the joint ab-
sence and joint presence of two or more of any side effects
would strongly outweigh any change in pain status.
None of the variables (age, sex, country, type of pain, pain self-
rating, and treatment history) were associated with strength of
preference, but respondents who had never discontinued chronic
pain medication exhibited a stronger total strength of preference
than thosewho had ever done so (P 0.013) (see Appendix 4 found
t doi:10.1016/j.val.2011.07.002).
Suffererswereasked to ratehowmuchpain they felt on their best
ays, on an average day, and on theirworst days. As shown in Figure
Fig. 3 – Sufferers’ self-reported p, mean pain scores were 4.0, 5.7, and 8.6 on these types of days,espectively, compared to the corresponding scores for the 84 focus
roup participants of 3.2, 5.1, and 8.2. Although pain experience was
idely dispersed on best days, ranging from 0 to 10, on worst days it
asmuchmore concentrated, with aminimum score of 4 andmore
han half of the respondents rating their pain at 9 or 10.
Physicians
A total of 606 physicians responded to the invitation to participate.
Of these, 303 were eliminated, principally due to failure to meet
the entry criteria for prescribing, leaving a study sample of 303
respondents who completed the questionnaire. Of these, 33 failed
the rationality test but none were nontraders, leaving an analysis
sample of 270. The distribution among countries was fairly even,
but we were able to recruit only 40 physicians who used classic
strong opioids for noncancer pain. Other respondent characteris-
tics are shown in Table 3.
The count data showed significant preferences between lev-
els for all five attributes and for the pain  nausea interaction
(P  0.01). MNL models incorporating interactions, however, did
not fit the data significantly better than a main-effects-only
model incorporating all five attributes, so the latter was selected
for the final hierarchical Bayesian estimation. Physicians’ mean
part-worths are shown in Figure 4. All preferences followed the
expected ordering 1  2  3. In the diagnostic tests, 245 of re-
spondents (91%) chose consistently, and the model correctly
predicted 236 of choices (96%) in the respective holdout tasks
(see Appendix 5 found at doi:10.1016/j.val.2011.07.002).
Physicians considered pain response to be the most impor-
tant attribute, accounting for 33% of their overall stated prefer-
ence. CNS side effects were the next most important attribute
(24%), followed by nausea (16%), dosage form (14%), and, ranked
least important, constipation (13%). Physicians viewed trading
up from the worst (level 3) attributes to level 2 as more impor-
tant than from level 2 to level 1. Such a nonlinear utility func-
tion is consistent with risk-averse behavior. For example, the
part-worth increment between a 25% and a 50% pain response
rate was twice that between a 50% and a 75% pain response rate,
even though both steps represent the same increment in num-
bers of patients who respond. A twofold difference was also
evident between the steps between levels of CNS side effects.
For dosage form, physicians only weakly preferred level 1,
which specified availability of transdermal, oral, and parenteral
forms, over level 2 (oral and parenteral only), whereas level 2
scores on 11-point Likert scale.ainwas strongly preferred to level 3 (parenteral only). The graph in
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to achieve an improvement from level 2 to level 1 in pain re-
sponse rate, physicians would accept a drop to level 3 constipa-
tion or nausea. They would be close to indifferent with respect
to loss of an oral dosage form, but they would not accept a drop
to level 3 CNS side effects. On the other hand, improvement in
side-effect attributes from level 2 to level 1, even all three side
effects jointly, would not increase utility enough to compensate
for a reduction in pain response rate from level 2 (50% response
rate) to level 3 (25% response rate).
Table 3 – Respondent characteristics: physicians.
Country and speciality
France
Primary care
Other speciality
Germany
Primary care
Other speciality
Italy
Primary care
Other speciality
Spain
Primary care
Other speciality
Sweden
Primary care
Other speciality
UK
Primary care
Other speciality
Total
Respondent characteristic
Age, in years
Time since qualified, in years
Time routinely treating chronic pain, in years
No. of patients seen per month requiring strong opioids
Practice location
Satisfaction with available strong opioids
TotalTreated indication was the only factor associated with totalstrength of preference. The minority of physicians (n  40) who
treat noncancer pain expressed greater strength of preference
than those who treat cancer pain (P  0.017). None of the other
factors were significantly associated with preference, suggest-
ing that physicians are fairly uniform in their preferences (see
Appendix 6 found at doi:10.1016/j.val.2011.07.002).
Comparisons between physicians’ and sufferers’ perceptions
Although it is not possible to compare physician and sufferer utilities
Indication treated, N
ancer pain Noncancer
pain
Total
43 3 46
23 1 24
20 2 22
42 6 48
22 3 25
20 3 23
38 8 46
16 4 20
22 4 26
36 8 44
15 5 20
21 3 24
37 5 42
27 0 27
10 5 15
34 10 44
17 5 22
17 5 22
230 40 270
Category N Proportion,
%
30–39 51 19
40–49 102 38
50–59 100 37
60 17 6
10 37 14
10–20 113 42
20–30 103 38
30 17 6
10 96 36
10–20 117 43
20–30 55 20
30 2 1
10–20 97 36
20–40 73 27
40–60 44 16
60–100 39 14
100 17 6
based 150 56
ital based 72 27
office and hospital based 48 18
satisfied 24 9
satisfied 197 73
ral 34 13
dissatisfied 14 5
dissatisfied 1 0
270 100C
Office
Hosp
Both
Very
Fairly
Neut
Fairly
VerybecausetheDCEsdifferedbetweenthetwogroups, theattributescanbe
a
s
r
p
115V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 6 – 1 1 7contrasted qualitatively. Figure 5 displays the five attributes ratedmost
important by each group in the qualitative research and ranks themby
proportions of total strength of preference. Pain, nausea, CNS, and con-
stipation-related attributes were important to both the pain sufferers
and physicians. Subject to caveats about the differences in question
framing, theDCEsuggests thatphysiciansmayplaceagreaterdegreeof
Fig. 4 – Estimated meanpart-worths for physicians (N = 270). The
ttribute and level and a constant term for each individual. The ta
tatistics; the means represent the regression coefficients in the e
elative importance of each attribute. The chart expresses the me
urposes of illustrating likely trading behavior. The pseudo R2 vaemphasis on pain than do sufferers within their respective patterns ofpreference. In contrast, pain sufferers expressed stronger preferences
than physicianswith respect to nausea. In the qualitative study, physi-
cians drew less distinction between different types of CNS side effects
thanpainsufferers,whoreportedproblemswithenergyandmotivation
as quite distinct from alertness and mental acuity. Constipation fol-
lowednauseaandCNSsideeffects inimportancetobothgroups.Choice
archical Bayesian model estimates mean part-worths for each
hows means and 95% confidence intervals (CIs) of these
ated main-effects model. The mean magnitudes represent the
art-worths as differences in utility between levels for the
a hierarchical Bayesian measure of the model fit.hier
ble s
stim
an p
lue isofdosage formwas important tophysicians,accounting for14%of their
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needs.
Discussion and Conclusions
This study yielded a great deal of information, both qualitative and
quantitative, about the preferences of individuals with chronic
pain and treatedwith classic strong opioids and of physicians pro-
viding treatment. The trade-off between effectiveness and side
effects was immediately apparent from the qualitative research
with pain sufferers and physicians.
The study identified that the most important concerns of suffer-
ers and physicians, which overlapped to a substantial degree but,
unsurprisingly, were expressed in different ways by the two groups.
Physicians gave greatest priority to pain control, whereas pain suf-
ferers were most concerned about avoiding nausea, with an impact
onpainonly the secondpriority.Moreover, attribute importancewas
more evenly distributed for pain sufferers, suggesting that they are
likely to trade off efficacy and tolerability to allow them to perform
daily activities. Among the types of side effects, pain sufferers were
most concerned about nausea, which ranked only third in the phy-
sicians’ ranking. Overall CNS effects occupied second place in physi-
cians’ rankings,whereasCNSmanifestationsof energyandalertness
were their third and fourth most important attributes for sufferers.
Physicians and sufferers agreed, however, that constipation was the
least important attribute each group considered; even so, it was one
of the five most important attributes of a long list of side effects
mentioned by respondents in the qualitative research, indicating
that constipation is a real concern.
Physicians described pain control in quantitative terms, which
is unsurprising given the widespread use of pain scales and ques-
tionnaires. Sufferers, however, expressed pain in terms of its im-
pact on activities of daily living. As for side effects, physicians
expected patients to encounter these to a greater or lesser extent,
providing advice andmanaging according to the degree of intoler-
ability. The prospect of severe side effects was such a concern for
pain sufferers that they opted for neither profile when faced with
sufficiently undesirable side effects in both profiles of a choice set,
sometimes refusing even highly effective treatment. This appears
to be consistent with previously described behavior [1]. Not sur-
prisingly, when asked about their aspirations for new treatments,
sufferers were most interested in improvements in tolerability.
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Fig. 5 – Attribute importance: comparison of pain sufferers’
experiments were specified differently between the two res
This chart shows each group’s five top-rated attributes as id
importance. CNS, central nervous system.They would also like to reduce the pill burden.The representativeness of Internet-based survey samples may
be imperfect because patients who are able and prepared to re-
spond via the Internet may differ systematically from the popula-
tion from which they are drawn. In a Swedish study recently pub-
lished in this journal [17], a cohort of total hip replacement
patients was randomized to receive invitations to rate health-re-
lated quality of life (by EuroQoL-5D [EQ-5D] profile and Visual An-
alogue Scale [VAS]) using either a traditional pen and paper or an
Internet questionnaire. The initial response rate was greater for
the traditional method, with a marked age gradient in responding
to the Internet method, but not to the traditional one. Internet
respondents provided higher EQ-5D index and VAS self-ratings,
independent of age and sex. Nonresponders were offered the op-
portunity to cross over to the opposite method, which prompted
substantial increases in response, with older subjects tending to
accept the pen-and-paper but not the Internet questionnaire invi-
tation. The authors concluded that Internet-only approaches in
patient-reported outcome studies are insufficient, and they rec-
ommend the use of a combined traditional plus Internet approach.
In the current Internet-only study, the shortcomings described
arguably apply more to the pain sufferers than to the physicians
because the latter group has becomeprofessionally accustomed to
the Internet in recent years, with the advent of electronic records
and online pharmacopoeias. In the pain sufferer sample, some
93% of respondents were white, and more than half (53%) had
continued full-time education until they were older than 18 years
of age, and 31% until they were older than 21 years of age. This
largely white and comparatively well-educated study population
cannot be considered as representative of the broader European
population taking opioid medication for chronic pain, so the re-
sults should not be seen as generalizable. Although we had in-
tended to recruit physicians evenly in terms of pain indication
treated, we were able to find only 40 physicians who met the in-
clusion criteria for noncancer pain.
The hierarchical Bayesian estimation used in this study gener-
ates part-worths for each individual, whereas traditional models
estimate values for the aggregate sample. Potentially, this allows
preference heterogeneity to be explored. Among the wide range of
factors tested, only “treated indication” (for physicians) and “past
discontinuation of pain medication” and “pain at the most severe
level” (for sufferers) were significantly associated with strength of
preference; no country or demographic effects were observed. The
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117V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 0 6 – 1 1 7because it derives the priors from the entire population, which is
assumed to be homogeneous. The most recent release of the soft-
ware allows this assumption to be relaxed, butwas not available to
us at the time of analysis.
Stated preference data of this kind lend themselves well to
defining the relative attractiveness of hypothetical or actual prod-
uct profiles. Adding the regression coefficients for attributes and
the constant gives the total utility of a profile. Whether such a
calculation accurately predicts choice behavior depends on how
well the regression model is specified. The physician model per-
formedwell, with preferences in the expected order and high con-
sistency and predictive power. The pain sufferer model, however,
performed less satisfactorily, even though all main effects were
significant. We believe that this is explained by the profiles tested.
The experimental design made undesirable profiles appear as fre-
quently as more desirable ones, possibly explaining why pain suf-
ferers frequently chose the opt-out. Although this affected the
reliability of the model, arguably it represents real life quite well,
when one considers the substantial proportions of chronic pain
sufferers who had not taken or lapsed taking strong opioids in the
European survey reviewed previously [1], and the 55% of pain suf-
ferers in our sample who had ever discontinued their pain medi-
cation. A possible solution to improve the model performance
would be to present side effects over a narrower, less severe range.
Another would be to present side effects as probabilities rather
than certainties, as was done with physician sample. We did not
do so in the belief that sufferers of severe chronic painmight have
difficulty understanding choices presented as probabilities. In ret-
rospect, our results suggest a need for further research into how
best to select and frame choice tasks in this area of medicine.
The pain status of the chronic pain sufferers was relatively
severe, as expected for those requiring treatment with opioids.
Our findings confirm the substantial unmet need for better toler-
ated opioidmedications to allow sufferers of cancer pain and non-
cancer chronic pain to achieve adequate pain control and enjoy an
improved quality of life.
Acknowledgments
The contributions of the coauthors were as follows: i3 Innovus
designed and directed the study (J.C., M.M.); the sponsor, through
H.L., collaborated in all aspects of the study design but not in the
analysis. Several organizations contributed to the fieldwork under
the direction of i3 Innovus. The focus groups were conducted by
Zagabria Medical in the UK and by EUMARA in the remaining
countries. i3 Innovus devised interviewguides for the focus groups
and the physician surveys and conducted the latter. i3 Innovus
devised the questionnaires and choice profiles for themain study.
Opinion Research Corporation translated, programmed, and ad-
ministered the questionnaires and provided the study database to
i3 Innovus for analysis. Research Now and WorldOne Research
provided the panels from which the sufferer and physician sam-
ples, respectively, were recruited. J.C. performed the analyses and
drafted the manuscript, which was reviewed and edited by M.M.,
H.L., M.B., and G.M.-S.The authors acknowledge the helpful advice received from
several clinicians and researchers, in particular, Phil Wiffen of the
UK Cochrane Centre; Dr. Simon Allard, consultant rheumatologist
at the West Middlesex Hospital, Isleworth, London; and Professor
Gérard de Pouvourville of ESSEC Business School, Paris. Benedikte
Lensberg and Raquel Aguiar-Ibañez of i3 Innovus conducted sev-
eral of the qualitative interviews.
Source of financial support: The study was entirely sponsored
by Grünenthal GmbH, Aachen, Germany.
Supplemental Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at doi:10.1016/j.jval.2011.07.002,
or if hard copy of article, atwww.valueinhealthjournal.com/issues
(select volume, issue, and article).
R E F E R E N C E S
[1] Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in
Europe: prevalence, impact on daily life, and treatment. Eur J Pain
2006;10:287–333.
[2] Hanks GW, Conno F, Cherny N, et al. Morphine and alternative
opioids in cancer pain: the EAPC recommendations. Br J Cancer
2001;84:587–93.
[3] Quigley C. The role of opioids in cancer pain. BMJ 2005;331:825–9.
[4] The British Pain Society. Cancer Pain Management. London: The British
Pain Society, 2010. Available from: http://www.britishpainsociety.
org/book_cancer_pain.pdf. [Accessed March 22, 2010].
[5] Kalso E, Allan L, Dellemijn PL, et al. Recommendations for using
opioids in chronic non-cancer pain. Eur J Pain 2003;7:381–6.
[6] Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-
cancer pain: systematic review of efficacy and safety. SO: Pain 2004;
112:372–0.
[7] Louviere JJ, Hensher DA, Swait JD. Stated Choice Methods: Analysis
and Application. Cambridge: Cambridge University Press, 2000.
[8] Lancsar E, Louviere J. Conducting discrete choice experiments to
inform healthcare decision making: a user’s guide.
Pharmacoeconomics 2008;26:661–77.
[9] Ryan M, Farrar S. Using conjoint analysis to elicit preferences for
health care. BMJ 2000;320:1530–3.
[10] Aakvik A, Holmas TH, Kjerstad E. A low-key social insurance reform–
effects of multidisciplinary outpatient treatment for back pain
patients in Norway. J Health Econ 2003;22:747–62.
[11] Chuck A, AdamowiczW, Jacobs P, et al. The willingness to pay for
reducing pain and pain-related disability. Value Health 2009;12:498–506.
[12] Ratcliffe J, Buxton M, McGarry T, et al. Patients’ preferences for
characteristics associated with treatments for osteoarthritis.
Rheumatology (Oxford) 2004;43:337–45.
[13] Sampietro-Colom L, Espallargues M, Rodriguez E, et al. Wide social
participation in prioritizing patients on waiting lists for joint
replacement: a conjoint analysis. Med Decis Making 2008;28:554–66.
[14] Schmier JK, Palmer CS, Flood EM, Gourlay G. Utility assessments of
opioid treatment for chronic pain. Pain Med 2002;3:218–30.
[15] Bradley N. Qualitative Research. Marketing Research: Tools and
Techniques. Oxford: Oxford University Press, 2010.
[16] Sawtooth Software. The CBC/HB System for Hierarchical Bayes
Estimation Version 5.0 Technical Paper. 2010. Available from: http://
www.sawtoothsoftware.com/education/techpap.shtml. [Accessed
December 27, 2010].
[17] Rolfson O, Salomonsson R, Dahlberg LE, Garellick G. Internet-based
follow-up questionnaire for measuring patient-reported outcome after
total hip replacement surgery-reliability and response rate. Value
Health 2011;14:316–21.
